Springboard’s Life Sciences Innovation Program is for women-led life sciences companies seeking growth, funding, and connections to experts and strategic partners for product development and expansion.
Now Open!
February 2023
February 2023
March 2023
Q2-Q3 2023
Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer.
NanoTess Inc. is a material science startup developing nanomaterials to address some of the world’s toughest health challenges, beginning with chronic wounds.
Lantern Laboratory is developing a novel device/platform utilizing EEG biomarkers to specifically guide pharmacological decisions during administration of analgesics and sedatives in operating rooms and intensive care, resulting in faster, safer awakenings from anesthesia, less postoperative neurocognitive dysfunction, and a reduction in the lifetime risk of dementia in those undergoing surgery or ICU stay.
Cayuga Biotech is developing first-in-class medicines that harness the body’s innate ability to stop bleeding and heal.
PTM Therapeutics is a pre-clinical stage startup developing antibody therapeutics against post-translational modification targets with programs in Inflammatory Bowel Disease and Oncology.
APIE Therapeutics is a biopharma start-up pioneering the development of a portfolio of anti-fibrotic therapeutics drugs to treat chronic and debilitating diseases associated with injury to the vascular endothelium organ.
Yaso is a preclinical drug development company focuses on the global need for non-hormonal contraceptives and disease prevention.
Minutia is working on a functional cure for Type 1 Diabetes by developing a subcutaneous transplant of insulin-producing cells delivered through a simple procedure and customized for engraftment success, enabled by a proprietary cell sensing platform.
Lavaage is bringing antivirals to consumer health with a proprietary platform of polysaccharide-based drugs derived from seaweed.
